drachma
if you're talking about a hostile takeover, IMO that's not on the cards as management have massive holdings to resist such a move. I forget the figures but check out the MSB website and it's there.
Ilescu has a few clues about the vulnerability of australian biotechs in the past and has taken preventive measures.
Further, the 'deal of the year' 2010 between Cepahlon/now Teva and MSB was not awarded for no reason. Ilescu has a few clues.
IMO.
DV
setting the record straight, page-20
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.07 |
Change
-0.055(4.89%) |
Mkt cap ! $1.221B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.16 | $1.06 | $8.816M | 8.055M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 280000 | $1.07 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.07 | 2000 | 1 |
View Market Depth
| Last trade - 16.10pm 29/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |